Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674854 · ClinicalTrials.gov registry record · Phase 3
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT02674854 is a Phase 3 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 750 participants.
The verdict
NCT02674854, a Phase 3 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
Interventions
- DRUG PG324 Ophthalmic Solution 0.02%/0.005%
- DRUG Netarsudil (AR-13324) ophthalmic solution 0.02%
- DRUG Latanoprost ophthalmic solution 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674854
The ClinicalTrials.gov registry entry for NCT02674854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PG324 Ophthalmic Solution 0.02%/0.005% is the first listed.
NCT02674854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674854 about?
NCT02674854 is a clinical study titled "Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension". To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
What is the current status of trial NCT02674854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2016-02. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02674854?
The interventions under investigation include: PG324 Ophthalmic Solution 0.02%/0.005% (DRUG), Netarsudil (AR-13324) ophthalmic solution 0.02% (DRUG), Latanoprost ophthalmic solution 0.005% (DRUG).
Who is sponsoring clinical trial NCT02674854?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.